News

Results from the company’s investigational study suggested that Orencia reduced flare-ups of the disease in children who were not helped by other anti-rheumatic drugs such as methotrexate or

The FDA issued its third approvable letter, stating that Encysive’s development program for Thelin did not demonstrate the evidence of effectiveness needed for approval. The FDA did note,

The FDA based its decision on results from a randomized, open-label, two-way crossover study of 16 healthy male subjects who received an intravenous infusion of Apidra or regular

Perlegen will use these samples to identify genetic variations that may contribute to a patient’s risk of experiencing adverse events. Results of these analyses may help to direct

The funding from the university will be available on September 1, 2007. Accordingly, ABI will immediately commence preparation of the investigational new drug (IND) application to the FDA.

According to data presented at the Annual European Congress of Rheumatology, Remicade (infliximab)-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance

GlycoPEGylated Factor VIIa is being developed by Novo Nordisk under a license agreement with Neose. The initiation of the phase I study triggers an undisclosed milestone payment to

This action will enable patients currently enrolled in the Assist-3 and Assist-5 trials the opportunity to continue to receive study treatments, including Telcyta in combination with chemotherapy, subject

Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline’s Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The company intends to launch the